UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Link zum Volltext

Verfügbarkeit prüfen

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-04, Vol.29 (12), p.1556-1563

2011

Link zum Volltext

Verfügbarkeit prüfen

Temperature-Dependent Infrared Refractive Index of Polymers from a Calibrated Attenuated Total Reflection Infrared Measurement

Applied spectroscopy, 2022-10, Vol.76 (10), p.1254-1262

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

The American journal of pathology, 2011-03, Vol.178 (3), p.989-996

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clinical cancer research, 2012-06, Vol.18 (11), p.3163-3169

2012

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Clinical cancer research, 2015-08, Vol.21 (15), p.3412-3419

2015

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

The American journal of pathology, 2009-08, Vol.175 (2), p.808-816

2009

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Link zum Volltext

Verfügbarkeit prüfen

ZD1839 (Iressa™): For More Than Just Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2002-08, Vol.7 (S4), p.16-24

Ranson, Malcolm

2002

Link zum Volltext

Verfügbarkeit prüfen

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2240-2250

2002

Link zum Volltext

Verfügbarkeit prüfen

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Clinical cancer research, 2010-12, Vol.16 (24), p.6150-6158

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1660-1666

2009

Link zum Volltext

Verfügbarkeit prüfen

Multiplexed Assays for Detection of Mutations in PIK3CA

Clinical chemistry (Baltimore, Md.), 2008-04, Vol.54 (4), p.757-760

2008

Link zum Volltext

Verfügbarkeit prüfen

Single-dose clinical pharmacokinetic studies of gefitinib

Clinical pharmacokinetics, 2005-01, Vol.44 (11), p.1165-1177

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

Journal of clinical oncology, 2007-06, Vol.25 (18), p.2540-2545

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1743-1749

2001

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3266-3273

2007

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Neoplasia (New York, N.Y.), 2011-04, Vol.13 (4), p.339-347

2011

Link zum Volltext

Verfügbarkeit prüfen

Perspectives on Anti-HER Monoclonal Antibodies

Oncology, 2002-01, Vol.63 (1), p.17-24

2002

Link zum Volltext

Verfügbarkeit prüfen

Where next for gefitinib in patients with lung cancer?

The lancet oncology, 2006-06, Vol.7 (6), p.499-507

2006

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

Investigational new drugs, 2012-08, Vol.30 (4), p.1493-1500

2012

Link zum Volltext

Verfügbarkeit prüfen

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

Biomarker Insights, 2007-01, Vol.2, p.307-319

2007

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(105)
Dissertationen
(1)

Sprache

Englisch
(103)
Japanisch
(14)
Serbian
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(67)
Humans
(66)
Oncology
(50)
Female
(44)
Male
(39)
Middle Aged
(39)
Aged
(36)
Adult
(33)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Lung Neoplasms - Drug Therapy
(22)
Antineoplastic Agents - Therapeutic Use
(21)
Pharmacology. Drug Treatments
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Lung Neoplasms - Pathology
(16)
Antineoplastic Agents
(15)
Dose-Response Relationship, Drug
(15)
Neoplasms - Drug Therapy
(15)
Treatment Outcome
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Temperature-Dependent Infrared Refractive Index of Polymers from a Calibrated Attenuated Total Reflection Infrared Measurement

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

ZD1839 (Iressa™): For More Than Just Non‐Small Cell Lung Cancer

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Multiplexed Assays for Detection of Mutations in PIK3CA

Single-dose clinical pharmacokinetic studies of gefitinib

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non–Small-Cell Lung Cancer

Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer

Perspectives on Anti-HER Monoclonal Antibodies

Where next for gefitinib in patients with lung cancer?

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Suchergebnisse filtern